Rob Stein

Rob Stein is a correspondent and senior editor on NPR's science desk.

An award-winning science journalist with more than 25 years of experience, Stein mostly covers health and medicine. He tends to focus on stories that illustrate the intersection of science, health, politics, social trends, ethics, and federal science policy. He tracks genetics, stem cells, cancer research, women's health issues and other science, medical, and health policy news.

Before NPR, Stein worked at The Washington Post for 16 years, first as the newspaper's science editor and then as a national health reporter. Earlier in his career, Stein spent about four years as an editor at NPR's science desk. Before that, he was a science reporter for United Press International (UPI) in Boston and the science editor of the international wire service in Washington.

Stein is a graduate of the University of Massachusetts, Amherst. He completed a journalism fellowship at the Harvard School of Public Health, a program in science and religion at the University of Cambridge, and a summer science writer's workshop at the Marine Biological Laboratory in Woods Hole, Mass.

Stein's work has been honored by many organizations, including the National Academy of Sciences, the American Association for the Advancement of Science and the Association of Health Care Journalists.

The United States appears to be in the midst of an unusually severe flu season, officials at the federal Centers for Disease Control and Prevention said Friday.

The flu season started early, which is never a good sign, and the flu is already widespread throughout the country, the CDC's latest report shows. Half of states are reporting especially intense flu activity.

Copyright 2018 NPR. To see more, visit http://www.npr.org/.

RACHEL MARTIN, HOST:

Copyright 2018 NPR. To see more, visit http://www.npr.org/.

SCOTT SIMON, HOST:

Life expectancy in the U.S. fell for the second year in a row in 2016, nudged down again by a surge in fatal opioid overdoses, federal officials report Thursday.

"I'm not prone to dramatic statements," says Robert Anderson, chief of the mortality statistics branch at the National Center for Health Statistics. "But I think we should be really alarmed. The drug overdose problem is a public health problem, and it needs to be addressed. We need to get a handle on it."

Scientists have now edited genes inside mice to prevent a form of inherited deafness.

While cautioning that much more research is needed, the scientists said they hope the technique might someday be used to prevent deafness in children born in families with a history of genetic hearing loss.

Before that could happen, however, extensive tests would be needed to determine whether the treatment is safe — and whether it would actually work in humans.

The Food and Drug Administration Tuesday approved the first gene therapy to treat an inherited disease.

The treatment is called Luxturna, a genetically modified virus that ferries a healthy gene into the eyes of patients born with retinal dystrophy, a rare condition that destroys cells in the retina needed for healthy vision.

Updated at 4:17 p.m. ET to include comment from homeopathic pharmacists.

The Food and Drug Administration said it plans to crack down on the sale of some homeopathic products.

The agency unveiled a new, risk-based approach to regulating homeopathic treatments Monday that aims to protect the public from dangerous products.

It's a typical hectic morning at Michele Comisky's house in Vienna, Va., when she gets a knock on her front door.

"Hi, how are you?" Comisky says as she greets Keisha Herbin Smith, a research assistant at Georgetown University. "Come on in."

Comisky, 39, leads Herbin Smith into her kitchen.

Health officials are warning that the United States may have an unusually harsh flu season this year.

But they stress that flu seasons are notoriously difficult to predict, and it's far too early to know for sure what may happen.

Eli Wheatley and Christian Guardino are among a growing number of patients whose lives are apparently being saved or radically improved by gene therapy.

Wheatley, 3, of Lebanon, Ky., and Guardino, 17, of Patchogue, N.Y., were both diagnosed with what were long thought to be incurable genetic disorders. In the past, Wheatley's condition would have probably killed him before his first birthday. Guardino's would have blinded him early in life.

But after receiving experimental gene therapies, both seem to be doing fine.

Pages